Bonti Gets $11.7M For Aesthetic Medicine Efforts

Newport Beach-based Bonti, a biotechnology company which is developing a botulinum neurotoxin aimed at the aesthetic medicine market, has raised $11.7M in a Series B financing round. Bonti said the Series B funding was led by RBV Capital, and also included City Hill Ventures, Colt Ventures, and others, and also included a Series B expansion from JMCR Partners and HighLight Capital. RBV Capital adds Alexey Konov to the company's board as part of the funding. The company has now raised $20.6M in total for its efforts. Fauad Hasan is co-founder and CEO of Bonti. More information »